---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-26-026232"
form_type: "8-K"
ticker: "IONS"
cik: "0000874015"
company_name: "IONIS PHARMACEUTICALS INC"
filed_at: "2026-06-24T19:48:37+00:00"
generated_at: "2026-06-24T19:49:25.524102+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# FDA approves Ionis' TRYNGOLZA for severe hypertriglyceridemia, cuts pancreatitis risk 91%

## Summary
- FDA approved TRYNGOLZA (olezarsen) as adjunct to diet to reduce triglycerides and risk of acute pancreatitis in adults with sHTG (TG ≥500 mg/dL).
- Phase 3 CORE/CORE2: fasting TG lowered up to 72% vs placebo at 6 months; acute pancreatitis events reduced up to 91%.
- 86% of patients achieved TG <500 mg/dL at 12 months; NNT to prevent one acute pancreatitis: 20 overall, 4 in highest-risk subgroup.
- Available in 50 mg or 80 mg dose, self-administered monthly via autoinjector; U.S. launch expected in July 2026.
- This is Ionis' first independent commercial launch in a prevalent disease, marking a major milestone.

## SEC filing metadata
- accession: 0001140361-26-026232
- form_type: 8-K
- ticker: IONS
- cik: 0000874015
- company_name: IONIS PHARMACEUTICALS INC
- filed_at: 2026-06-24T19:48:37+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/874015/000114036126026232/0001140361-26-026232-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/874015/000114036126026232/ef20076807_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-26-026232
- JSON: https://secwatch.observer/filing/0001140361-26-026232.json
- Plain text: https://secwatch.observer/filing/0001140361-26-026232.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.